172 related articles for article (PubMed ID: 8775753)
1. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches.
Griffon N; Sokoloff P; Diaz J; Lévesque D; Sautel F; Schwartz JC; Simon P; Costentin J; Garrido F; Mann A
Eur Neuropsychopharmacol; 1995; 5 Suppl():3-9. PubMed ID: 8775753
[TBL] [Abstract][Full Text] [Related]
2. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
3. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.
Lévesque D; Martres MP; Diaz J; Griffon N; Lammers CH; Sokoloff P; Schwartz JC
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1719-23. PubMed ID: 7878047
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a functional role of the dopamine D3 receptors in the cerebellum.
Barik S; de Beaurepaire R
Brain Res; 1996 Oct; 737(1-2):347-50. PubMed ID: 8930390
[TBL] [Abstract][Full Text] [Related]
5. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats.
Chaki S; Funakoshi T; Yoshikawa R; Okuyama S; Kumagai T; Nakazato A; Nagamine M; Tomisawa K
Neuropharmacology; 1999 Aug; 38(8):1185-94. PubMed ID: 10462131
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat.
Barik S; de Beaurepaire R
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):718-26. PubMed ID: 15913875
[TBL] [Abstract][Full Text] [Related]
7. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
Wilson JM; Sanyal S; Van Tol HH
Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach.
Clifford JJ; Waddington JL
Psychopharmacology (Berl); 1998 Apr; 136(3):284-90. PubMed ID: 9566814
[TBL] [Abstract][Full Text] [Related]
10. [Functional role of dopamine D3 receptor in schizophrenia].
Semba J
Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
[TBL] [Abstract][Full Text] [Related]
11. Opposing roles for dopamine D2 and D3 receptors on neurotensin mRNA expression in nucleus accumbens.
Diaz J; Lévesque D; Griffon N; Lammers CH; Martres MP; Sokoloff P; Schwartz JC
Eur J Neurosci; 1994 Aug; 6(8):1384-7. PubMed ID: 7981879
[TBL] [Abstract][Full Text] [Related]
12. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine.
Richtand NM; Logue AD; Welge JA; Perdiue J; Tubbs LJ; Spitzer RH; Sethuraman G; Geracioti TD
Brain Res; 2000 Jun; 867(1-2):239-42. PubMed ID: 10837819
[TBL] [Abstract][Full Text] [Related]
13. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia.
Reynolds GP; Mason SL
Eur J Pharmacol; 1995 Aug; 281(2):R5-6. PubMed ID: 7589196
[TBL] [Abstract][Full Text] [Related]
14. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat.
Caine SB; Geyer MA; Swerdlow NR
Neuropsychopharmacology; 1995 Apr; 12(2):139-45. PubMed ID: 7779242
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
16. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
Gurevich EV; Bordelon Y; Shapiro RM; Arnold SE; Gur RE; Joyce JN
Arch Gen Psychiatry; 1997 Mar; 54(3):225-32. PubMed ID: 9075463
[TBL] [Abstract][Full Text] [Related]
17. Novel pharmacological approaches to the treatment of schizophrenia.
Fink-Jensen A
Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
[TBL] [Abstract][Full Text] [Related]
18. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
[TBL] [Abstract][Full Text] [Related]
20. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
